JP7242057B2 - 薬物性腎損傷を予防及び治療するための方法 - Google Patents

薬物性腎損傷を予防及び治療するための方法 Download PDF

Info

Publication number
JP7242057B2
JP7242057B2 JP2019531812A JP2019531812A JP7242057B2 JP 7242057 B2 JP7242057 B2 JP 7242057B2 JP 2019531812 A JP2019531812 A JP 2019531812A JP 2019531812 A JP2019531812 A JP 2019531812A JP 7242057 B2 JP7242057 B2 JP 7242057B2
Authority
JP
Japan
Prior art keywords
plasminogen
renal
administered
mice
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019531812A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020502135A (ja
JP2020502135A5 (https=
Inventor
季男 李
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Talengen International Ltd
Original Assignee
Talengen International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Talengen International Ltd filed Critical Talengen International Ltd
Publication of JP2020502135A publication Critical patent/JP2020502135A/ja
Publication of JP2020502135A5 publication Critical patent/JP2020502135A5/ja
Application granted granted Critical
Publication of JP7242057B2 publication Critical patent/JP7242057B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019531812A 2016-12-15 2017-06-19 薬物性腎損傷を予防及び治療するための方法 Active JP7242057B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2016110174 2016-12-15
CNPCT/CN2016/110174 2016-12-15
CNPCT/CN2016/110169 2016-12-15
CN2016110169 2016-12-15
PCT/CN2017/089059 WO2018107699A1 (zh) 2016-12-15 2017-06-19 一种预防和治疗药物性肾损伤的方法

Publications (3)

Publication Number Publication Date
JP2020502135A JP2020502135A (ja) 2020-01-23
JP2020502135A5 JP2020502135A5 (https=) 2020-07-30
JP7242057B2 true JP7242057B2 (ja) 2023-03-20

Family

ID=62557856

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019531812A Active JP7242057B2 (ja) 2016-12-15 2017-06-19 薬物性腎損傷を予防及び治療するための方法
JP2019531809A Active JP7182793B2 (ja) 2016-12-15 2017-06-19 病理学的腎組織損傷を予防及び治療するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019531809A Active JP7182793B2 (ja) 2016-12-15 2017-06-19 病理学的腎組織損傷を予防及び治療するための方法

Country Status (7)

Country Link
US (2) US20190328848A1 (https=)
EP (2) EP3556388A4 (https=)
JP (2) JP7242057B2 (https=)
CN (2) CN110366427A (https=)
CA (2) CA3047171A1 (https=)
TW (4) TW202123962A (https=)
WO (3) WO2018107699A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7213552B2 (ja) 2016-12-15 2023-01-27 タレンゲン インターナショナル リミテッド 肝の繊維化を予防及び治療するための方法
CA3067890A1 (en) 2017-06-19 2018-12-27 Talengen International Limited Method for regulating and controling glp-1/glp-1r and drug
TWI868051B (zh) 2017-06-23 2025-01-01 美商波麥堤克生物治療股份有限公司 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療
CN113456579B (zh) * 2021-07-12 2023-04-25 南开大学 具有双靶点的hdac抑制剂的纳米胶束-水凝胶制剂在治疗急性肾损伤药物中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005519992A (ja) 2002-01-29 2005-07-07 キャリングタン、ラバラトーリズ、インク 増殖因子とプロテアーゼ酵素の組合せ
US20050250694A1 (en) 2003-10-10 2005-11-10 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
JP2010502600A (ja) 2006-08-28 2010-01-28 オムニオ・ヒーラー・アクチボラゲット 感染症に対する候補薬
JP2016529255A (ja) 2013-08-13 2016-09-23 サノフイ プラスミノーゲン活性化因子阻害剤−１（ｐａｉ−１）に対する抗体及びその使用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
CN87104683A (zh) * 1986-05-15 1988-12-21 埃默里大学 改善血纤维蛋白溶解作用的组合物
ES2434840T3 (es) 1995-07-27 2013-12-17 Genentech, Inc. Formulación de proteína liofilizada isotónica estable
MXPA04007585A (es) * 2002-02-06 2005-09-20 N Zyme Biotec Gmbh Metodo para la produccion de proteinas recombinantes en microorganismos.
JP2006507297A (ja) * 2002-05-13 2006-03-02 チルドレンズ・ホスピタル・ロサンジェルス ケロイドおよび他の皮膚または内部創傷または病変における異常瘢痕形成の処置および予防
CA2509170A1 (en) * 2002-12-10 2004-06-24 Wyeth Substituted 3-alkyl and 3-arylalkyl 1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
AU2005277137A1 (en) * 2004-08-23 2006-03-02 Wyeth Pyrrolo-naphthyl acids as PAI-1 inhibitors
US8741260B2 (en) 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
JP5736597B2 (ja) * 2009-05-26 2015-06-17 ウニベルシダド・デ・サラマンカ 急性腎不全又は急性腎不全発症リスクのマーカーとしての尿中ｇｍ２活性化タンパク質
KR20120050442A (ko) * 2009-07-10 2012-05-18 쓰롬보제닉스 엔.브이. 플라스미노겐 및 플라스민의 변이체
CN102121023B (zh) * 2010-12-22 2012-07-04 中山大学 突变型人纤溶酶原kringle5及其制备方法及应用
EP2661493B1 (en) * 2011-01-05 2016-03-30 ThromboGenics N.V. Plasminogen and plasmin variants
CN102154253A (zh) 2011-01-06 2011-08-17 郑州大学 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途
CN106913860A (zh) 2011-09-29 2017-07-04 梅约医学教育与研究基金会 芳族阳离子肽和使用它们的方法
PL3109320T3 (pl) * 2014-02-21 2019-08-30 Astellas Pharma Inc. Nowe przeciwciało anty-ludzki PAI-1

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005519992A (ja) 2002-01-29 2005-07-07 キャリングタン、ラバラトーリズ、インク 増殖因子とプロテアーゼ酵素の組合せ
US20050250694A1 (en) 2003-10-10 2005-11-10 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
JP2010502600A (ja) 2006-08-28 2010-01-28 オムニオ・ヒーラー・アクチボラゲット 感染症に対する候補薬
JP2016529255A (ja) 2013-08-13 2016-09-23 サノフイ プラスミノーゲン活性化因子阻害剤−１（ｐａｉ−１）に対する抗体及びその使用

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Curr. Diagn. Pathol. (2007) vol.13, issue 2, p.25-31
Heamostasis，1988年，Vol.18, Suppl.1，p.165-175
日腎会誌 (Oct 2016) vol.58, no.7, p.1064-1068
血栓止血誌 (2009) vol.20, no.1, p.23-26
血管と脈管，1981年，第１２巻、第４号，第４９３頁－第５０１頁

Also Published As

Publication number Publication date
JP2020502135A (ja) 2020-01-23
WO2018107695A1 (zh) 2018-06-21
US20190328848A1 (en) 2019-10-31
JP7182793B2 (ja) 2022-12-05
WO2018107699A1 (zh) 2018-06-21
TWI642441B (zh) 2018-12-01
EP3556386A1 (en) 2019-10-23
CA3047171A1 (en) 2018-06-21
CN110167582A (zh) 2019-08-23
CN110366427A (zh) 2019-10-22
TW201822797A (zh) 2018-07-01
EP3556388A1 (en) 2019-10-23
CA3047170A1 (en) 2018-06-21
JP2020502134A (ja) 2020-01-23
EP3556388A4 (en) 2020-07-08
WO2018107700A1 (zh) 2018-06-21
EP3556386A4 (en) 2020-07-08
TW201822793A (zh) 2018-07-01
TW201822794A (zh) 2018-07-01
US20190343930A1 (en) 2019-11-14
TW202123962A (zh) 2021-07-01
TWI661838B (zh) 2019-06-11

Similar Documents

Publication Publication Date Title
TWI750189B (zh) 一種治療冠狀動脈粥樣硬化及其併發症的方法
WO2017101868A1 (zh) 一种预防和治疗糖尿病肾病的方法
JP7242057B2 (ja) 薬物性腎損傷を予防及び治療するための方法
HK1257234A1 (zh) 治疗冠状动脉粥样硬化及其并发症的药物及其用途
WO2018107696A1 (zh) 一种预防和治疗肝纤维化的方法
WO2018107689A1 (zh) 一种预防和治疗脂质肾损伤的方法
HK1257591A1 (zh) 预防和治疗病理性肾组织损伤的药物及其用途
HK1257235A1 (en) Medicine for treating atherosclerosis and complications of atherosclerosis and use of the medicine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200616

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200616

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210706

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211001

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220725

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221229

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230131

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230301

R150 Certificate of patent or registration of utility model

Ref document number: 7242057

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250